Context

Voluntis is a digital therapeutics pioneer that empowers people suffering from chronic conditions to self-manage their treatment every day, thus improving real-world outcomes.

A portfolio of solutions targeting the world’s top two therapy areas: diabetes and cancer.

Partnerships with leading players in their respective fields: Sanofi, AstraZeneca, Roche, Google.

Vast program of clinical trials, with 5 successfully completed and 2 in progress.

Commercial launch underway for Diabeo® and Insulia® (therapeutic solutions for diabetes) in Europe and the US.

First payer contract announced with WelldyneRx.

120 employees located in Paris and Boston.

Use of proceeds include the scale-up of commercial activities in North America and Europe and the development of the company’s proprietary multi-cancer solution.

About Voluntis

Voluntis creates digital companions that empower people to self-manage their treatment in remote collaboration with their health care teams. Dedicated to chronic conditions, Voluntis’ products aim to personalize treatment, support team-care coordination and improve real-world outcomes. Voluntis leverages its expertise in digitizing clinical algorithms and its technology platform to design its companion solutions. These include Insulia and Diabeo in diabetes as well as eCO and Zemy in oncology. Voluntis has long-standing partnerships with leading life science companies such as Sanofi, Roche and AstraZeneca. It is a founding member of the Digital Therapeutics Alliance.

Discover Voluntis

Hervé Ronin

Investment Banking

Romain Ellul

Investment Banking

Pierre Cuer

Investment Banking

Pierre Lafitte

Investment Banking

Cosme Rosellini

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center